Hulse Raymond E, Ralat Luis A, Wei-Jen Tang
Committee on Neurobiology, The University of Chicago, Chicago, Illinois 60637, USA.
Vitam Horm. 2009;80:635-48. doi: 10.1016/S0083-6729(08)00622-5.
The short half-life of insulin in the human body (4-6 min) prompted the search and discovery of insulin-degrading enzyme (IDE), a 110-kDa metalloprotease that can rapidly degrade insulin into inactive fragments. Genetic and biochemical evidence accumulated in the last sixty years has implicated IDE as an important physiological contributor in the maintenance of insulin levels. Recent structural and biochemical analyses reveal the molecular basis of how IDE uses size and charge distribution of the catalytic chamber and structural flexibility of substrates to selectively recognize and degrade insulin, as well as the regulatory mechanisms of this enzyme. These studies provide a path for potential therapeutics in the control of insulin metabolism by the degradation of insulin.
胰岛素在人体中的半衰期较短(4 - 6分钟),这促使人们寻找并发现了胰岛素降解酶(IDE),一种110 kDa的金属蛋白酶,它能迅速将胰岛素降解为无活性的片段。过去六十年来积累的遗传学和生物化学证据表明,IDE是维持胰岛素水平的重要生理因素。最近的结构和生物化学分析揭示了IDE如何利用催化腔的大小和电荷分布以及底物的结构灵活性来选择性识别和降解胰岛素的分子基础,以及该酶的调节机制。这些研究为通过降解胰岛素来控制胰岛素代谢的潜在治疗方法提供了一条途径。